Commentary on “Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms”

Article information

Int Neurourol J. 2020;24(3):295-295

Publication date (electronic) : 2020 September 30

doi : https://doi.org/10.5213/inj.2040286.143

Lori Birder^,1,2

¹Department of Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

²Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA

Corresponding author: Lori Birder https://orcid.org/0000-0002-3393-2256 Department of Medicine, School of Medicine, University of Pittsburgh, A1219 Scaife Hall, Pittsburgh, PA 15261, USA E-mail: lbirder@pitt.edu

Received 2020 August 11; Accepted 2020 August 23.

This review discusses the correlation of various urologic medications and the possible effect on cognitive function in the older population [1]. This is extremely important considering the number of medications (including over the counter) that are prescribed for the older patient. For example, the authors subclassified anticholinergic medications according reports affecting cognitive function in patients [1]. Though useful information, further studies are needed to determine whether the risk for dementia taking these medications may differ in middle-aged versus the older patient. Further, the increased reliance on various types of over the counter medications (such as sleeping aids, many of which may mimic anticholinergic effects) may increase drug-drug interactions and in turn, risk of cognitive dysfunction [2]. It has been shown that patients diagnosed with dementia treated with cholinesterase inhibitors as well as antimuscarinics are likely to have a faster rate of cognitive decline [3]. The review discusses a number of drug classes (i.e., anticholinergics, alpha blockers, beta 3 agonists, 5 alpha-reductase inhibitor) but as the authors pointed out, it is unclear in many cases if long-term use increases the risk of dementia. Another unknown is whether adverse events can be reversed or normalized if the treatment is stopped [4]. The benefit or risk in each category is reviewed as seniors are at a higher risk to adverse events due to age-associated changes in drug metabolism, as well as the changes in the blood-brain barrier [5]. Overall, a better understanding of age-associated drug-drug interactions and a discussion of risks versus benefits of a medication is needed to reduce the incidence of long-term side effects in the older patient.